- Home
- FLC vs CHRS Comparison
FLC vs CHRS Comparison
Compare FLC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- CHRS
- Stock Information
- Founded
- FLC 2003
- CHRS 2010
- Country
- FLC United States
- CHRS United States
- Employees
- FLC N/A
- CHRS N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLC Finance
- CHRS Health Care
- Exchange
- FLC Nasdaq
- CHRS Nasdaq
- Market Cap
- FLC 180.6M
- CHRS 191.3M
- IPO Year
- FLC N/A
- CHRS 2014
- Fundamental
- Price
- FLC $16.75
- CHRS $1.49
- Analyst Decision
- FLC
- CHRS Strong Buy
- Analyst Count
- FLC 0
- CHRS 4
- Target Price
- FLC N/A
- CHRS $5.38
- AVG Volume (30 Days)
- FLC 37.8K
- CHRS 2.2M
- Earning Date
- FLC 01-01-0001
- CHRS 11-06-2024
- Dividend Yield
- FLC 6.64%
- CHRS N/A
- EPS Growth
- FLC N/A
- CHRS N/A
- EPS
- FLC N/A
- CHRS N/A
- Revenue
- FLC N/A
- CHRS $304,340,000.00
- Revenue This Year
- FLC N/A
- CHRS $2.47
- Revenue Next Year
- FLC N/A
- CHRS N/A
- P/E Ratio
- FLC N/A
- CHRS N/A
- Revenue Growth
- FLC N/A
- CHRS 44.19
- 52 Week Low
- FLC $12.62
- CHRS $0.66
- 52 Week High
- FLC $15.45
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- FLC 51.85
- CHRS 51.20
- Support Level
- FLC $16.46
- CHRS $1.44
- Resistance Level
- FLC $16.89
- CHRS $1.60
- Average True Range (ATR)
- FLC 0.21
- CHRS 0.13
- MACD
- FLC 0.00
- CHRS -0.02
- Stochastic Oscillator
- FLC 70.00
- CHRS 30.95
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.